

# A Frameshift Mutation in *GRXCR2* Causes Recessively Inherited Hearing Loss

Ayesha Imtiaz,<sup>1</sup> David C. Kohrman,<sup>2</sup> and Sadaf Naz<sup>1\*</sup>

<sup>1</sup>School of Biological Sciences, University of the Punjab, Lahore, Pakistan; <sup>2</sup>Department of Otolaryngology, Kresge Hearing Research Institute, University of Michigan Medical School, Ann Arbor, Michigan 48109

Communicated by Andreas Gal

Received 4 January 2014; accepted revised manuscript 4 March 2014.

Published online 11 March 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22545

**ABSTRACT:** More than 360 million humans are affected with some degree of hearing loss, either early or later in life. A genetic cause for the disorder is present in a majority of the cases. We mapped a locus (*DFNB101*) for hearing loss in humans to chromosome 5q in a consanguineous Pakistani family. Exome sequencing revealed an insertion mutation in *GRXCR2* as the cause of moderate-to-severe and likely progressive hearing loss in the affected individuals of the family. The frameshift mutation is predicted to affect a conserved, cysteine-rich region of *GRXCR2*, and to result in an abnormal extension of the C-terminus. Functional studies by cell transfections demonstrated that the mutant protein is unstable and mislocalized relative to wild-type *GRXCR2*, consistent with a loss-of-function mutation. Targeted disruption of *Grxcr2* is concurrently reported to cause hearing loss in mice. The structural abnormalities in this animal model suggest a role for *GRXCR2* in the development of stereocilia bundles, specialized structures on the apical surface of sensory cells in the cochlea that are critical for sound detection. Our results indicate that *GRXCR2* should be considered in differential genetic diagnosis for individuals with early onset, moderate-to-severe and progressive hearing loss.

Hum Mutat 35:618–624, 2014. © 2014 Wiley Periodicals, Inc.

**KEY WORDS:** *DFNB101*; deafness; progressive; moderate to severe; *GRXCR2*; Pakistan

## Introduction

Auditory thresholds in affected individuals with recessively inherited deafness can range from mild to profound hearing loss, which can be stable or progressive in nature. Among the nonsyndromic forms, up to 85% of inherited deafness is autosomal recessive and exhibits high genetic heterogeneity, with more than 75 associated loci known currently (The Hereditary Hearing Loss Homepage [<http://hereditaryhearingloss.org/>]). While homozygous mutations

in a small subset of the identified genes result in less severe and/or progressive hearing loss [Naz 2012; Schraders et al., 2012; Schrauwen et al., 2012; Yariz et al., 2012; Girotto et al., 2013; Horn et al., 2013], a majority of the known recessive mutations are associated with profound, congenital deafness. Conversely, a high proportion of humans suffer from a progressive or early onset, less severe hearing loss, which suggests that alternative mutations in known or novel genes contributing to this phenotype remain unidentified.

Globally, mutations in *TECTA* (MIM #602574), *STRC* (MIM #606440), *CABP2* (MIM #607314), *OTOGL* (MIM #614925), and *BDP1* (MIM #607012) have been reported to cause moderate-to-severe hearing loss, whereas mutations in *OTOG* (MIM #604887) result in moderate hearing loss. Consanguineous families from Pakistan have played a significant role in mapping and identification of genes required for audition, especially those that on disruption cause recessively inherited profound deafness. Similar progress has not been made in identification of genes involved in moderate-to-severe hearing loss. We sought to study this phenotype in Pakistani families and here report a mutant allele of *GRXCR2* associated with recessively inherited, moderate-to-severe hearing loss in humans.

## Materials and Methods

### Ethics Statement

Institutional review board at the School of Biological Sciences, University of the Punjab, Lahore, Pakistan approved the study prior to the commencement of research, and sampling was conducted with written informed consent of all participants.

### Subjects

We investigated individuals affected with moderate-to-severe hearing loss in a cohort that included 80 consanguineous families with three or more affected individuals (Naz S, unpublished data). We also included samples from 55 sporadic individuals born in consanguineous marriages with no known environmental causes for their hearing loss and who were negative for mutations in *GJB2* and other common genes involved in hearing loss. The ears of the participants were clinically examined by an ENT (ear, nose, and throat) doctor. Hearing was evaluated by pure-tone audiometry at frequencies of 250, 500, 2,000, 4,000, and 8,000 Hz in ambient noise conditions. Clinically, hearing loss was defined as moderate (41–55 dB), moderate-to-severe (56–70 dB) or severe hearing loss (71–90 dB), respectively. Vestibular dysfunction or balance issues were evaluated by Romberg and Tandem gait tests. Funduscopy

Additional Supporting Information may be found in the online version of this article.

Contract grant sponsors: Fogarty International Center and National Institute of Deafness and Other Communication Disorders, National Institutes of Health (grants R01TW007608, R01-DC003049, P30-DC005188); Margaret G. Bertsch Endowed Research Fund.

\*Correspondence to: Sadaf Naz, School of Biological Sciences, University of the Punjab, Quaid-i-Azam Campus, Lahore 54590, Pakistan. E-mail: naz.sbs@pu.edu.pk

and electroretinography were conducted to detect onset of retinitis pigmentosa.

## Homozygosity Mapping

Known genes for hearing loss including those for Usher syndromes were excluded by linkage analyses with polymorphic markers [Imtiaz and Naz, 2012]. Genome-wide homozygosity mapping was performed for three individuals in family HLAI-05 (one unaffected mother and her two affected offspring) on SNP data obtained from Affymetrix Genome-wide Human SNP array 6.0 (Atlas Biolabs, Berlin, Germany). Regions of shared homozygosity between the two affected were searched with KinSNP [Amir et al., 2010]. For these analyses, a minimum block threshold was set at 0.5 cm and the confidence cutoff values for SNPs were set at 0.1. A heterozygous SNP in any stretch of 10 homozygous SNPs was ignored in order not to miss regions of homozygosity due to erroneous allele calls.

## Whole-Exome Sequencing

Whole-exome sequencing was performed for individual V:3 using Agilent V4 enrichment kit (Agilent Technologies, Santa Clara, CA) and paired-end reads were obtained at 50× coverage on an Illumina Hi-Seq 2000 sequencer (OtoGenetics, Norcross, GA). The reads were mapped to UCSC hg19 reference human genome (<http://genome.ucsc.edu/>). The data were analyzed and variants were filtered using the DNAnexus software (DNAnexus, Mountain View, CA). Known SNPs in dbSNP132 were filtered out. Data from known deafness genes were examined for mutations. Subsequent analysis was confined to the mapped *DFNB101* linkage interval.

Primers were designed (Supp. Table S1) using the online program primer 3 (<http://bioinfo.ut.ee/primer3-0.4.0/>). All primer pairs except *PCDHGA12* were used to PCR amplify the respective exons with surrounding intronic regions in 25  $\mu$ l reactions at 2 mM final MgCl<sub>2</sub> concentration using a touchdown protocol from 65°C to 55°C. *PCDHGA12* exon was GC-rich and was amplified by a different protocol (Supp. Table S1). All PCR products were purified and sequenced using Big Dye Terminators v3.1 (Applied Biosystems, Foster City, CA). Frequency of mutations in *SPOCK1*, *PCDHGA12*, and *GRXCR2* was checked by allele-specific PCR in normal control samples (Supp. Table S2). We submitted the novel variants that we identified to dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>).

## Protein Alignment and Prediction

GRXCR2 orthologous protein sequences were obtained from Ensembl Genome Server ([www.ensembl.org](http://www.ensembl.org)). Multiple sequence alignments of the protein sequences were carried out using CLUSTALO (<http://www.ebi.ac.uk/Tools/msa/clustalo/>). Protein structural predictions and homology searches were performed by Predict Protein (<https://www.predictprotein.org/>) and NCBI BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>).

## Transfection Constructs and Assays

Human inner ear tissue was obtained with appropriate informed consent and under the approval of the University of Michigan Institutional Review Board (IRB HUM00051822). Total RNA was prepared from human inner ear tissue using Trizol (Life Technologies, Grand Island, NY); reverse transcribed using oligo dT


primers, amplified with primers designed from wild-type human *GRXCR2* cDNA sequence (NM\_001080516.1; forward primer: gtgaattccaccatggagcagaagctgatctcagaggaggacctgGAGGACCTGAGAAAAGCTGAA; reverse primer: gtggatccGGAAGGATAATTTTGAACCAGTTTCAA), and cloned into the *EcoRI*–*BamHI* sites of the expression vector pIRES-eGFP (Clontech, Mountain View, CA). The forward primer included an in-frame myc epitope coding region (underlined) to permit translation of an N-terminally tagged GRXCR2 protein. The reverse primer is complementary to 3' UTR sequences that extended 248 nucleotides 3' of the wild-type translation stop codon and 60 nucleotides 3' of the new stop codon predicted from the frameshift in the c.714dupT transcript. The pIRES vector is designed to coexpress eGFP from a downstream internal ribosome entry site. The c.714dupT variant was introduced into the wild-type cDNA using the QuikChange II XL Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Agilent Technologies). Clones were confirmed by Sanger sequencing.

## Immunocytochemistry

LLC-PK1–CL4 (CL4) epithelial cells on glass coverslips were transfected with *GRXCR2* expression constructs (2  $\mu$ g per coverslip) using Lipofectamine LTX (Life Technologies). Cells were fixed 24 hr after transfection in 2% paraformaldehyde, permeabilized with 0.1% Triton X-100, and washed in PBS. Cells were then treated with 5% goat serum in PBS for 1 hr and incubated with a mouse anti-myc monoclonal antibody (catalogue number 05-419 [9E10]; Millipore, Billerica, MA). After washing in PBS, cells were incubated with antimouse IgG-Alexa 594 secondary antibodies (Life Technologies). Native fluorescence from the GFP reporter protein was augmented by coincubation with anti-GFP antibodies (Cell Signaling Technology, Boston, MA) and antirabbit IgG-Alexa 488 secondary antibodies. Nuclei and actin filaments were stained using Hoechst reagent and phalloidin-Alexa 647 (Life Technologies). Following additional PBS washes and mounting with Prolong Gold (Life Technologies), cells were imaged using a Nikon A1 confocal microscope with an oil-immersion objective (60×, 1.4 numerical aperture). Orthogonal sections (x, z) were generated using Imaris 7.6 software (Bitplane, Zurich, Germany). Colocalization of myc-GRXCR2 and actin filament immunoreactivity was quantitatively evaluated by the Imaris software, using its automatic thresholding function [Costes et al., 2004].

## Western Blot Analysis

Human embryonic kidney 293T cells in 6-well plates were transfected with *GRXCR2* expression constructs (2  $\mu$ g per well) using Lipofectamine LTX (Life Technologies). Transfected cells were treated with the reversible proteasome inhibitor MG132 (Cayman Chemical, Ann Arbor, MI) at a final concentration of 20  $\mu$ M or with ethanol vehicle. Whole-cell protein lysates were prepared approximately 24 hr after transfection (6 hr after treatment with MG132 or ethanol) in RIPA buffer (150 mM NaCl; 1.0% NP-40; 0.5% sodium deoxycholate; 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with a protease inhibitor cocktail (Roche, Indianapolis, IN) and 0.3 mM phenylmethylsulfonyl fluoride. Protein concentrations of each lysate were measured using the DC assay system (Biorad, Hercules, CA). Equivalent amounts of total protein were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose filters. Filters were blocked with 5% dry milk in PBS/0.05% Tween 20 and sequentially incubated with a mouse monoclonal antibody specific for myc (catalog number R950-25; Life Technologies) and



**Figure 1.** Mapping of *DFNB101*, audiograms, and frameshift *GRXCR2* variant cosegregating with hearing loss. **A:** Family HLAI-05. Black symbols represent affected individuals, whereas the dots in squares and circles indicate the mutation carriers. The *DFNB101*-linked haplotype with alleles of STR markers spanning chromosome 5 is shaded in gray. Map distances are according to the Rutgers' map (<http://compgen.rutgers.edu/RutgersMap>). *C5SCAB1* is a custom-generated marker to genotype repeats present at chr5:126250460–126250504 according to hg19 assembly. The *GRXCR2* mutation is shown ("+", wild-type allele; "-", dupT allele). Samples from IV:2, V:1, and V:3 were used for the SNP homozygosity screen, whereas that of V:5 was used for exome sequencing. **B:** Audiograms from selected individuals in family HLAI-05. Thresholds reveal the presence of moderate-to-severe, sensorineural hearing loss, which was reported to be early in onset in the three affected individuals. For clarity, thresholds are shown for one ear from each individual. There was no difference in hearing between the two ears of an affected person. Note that the younger individuals have a less severe hearing loss as compared with the older affected individual, which suggests that the loss in hearing is progressive in nature. **C:** Partial chromatograms from *GRXCR2* exon 3 from an affected and a control individual, respectively. The duplicated "T" residue is underlined.

antimouse IgG conjugated to horseradish peroxidase (ThermoScientific, Waltham, MA). Immune complexes were detected with SuperSignal West Femto Chemiluminescent Substrate (ThermoScientific) and imaged with a CCD camera. Following detection of myc hybrid proteins, the immune complexes were removed from the filters with Restore Western Blot Stripping Buffer (ThermoScientific) and GFP was detected using a rabbit anti-GFP antibody (Cell Signaling) and anti-rabbit IgG conjugated to horseradish peroxidase.

## Results

Family HLAI-05 (Fig. 1A) was ascertained from Punjab. Examinations of the ears of the affected individuals showed intact tympanic membranes and excluded inner ear infections as a cause of hearing loss. Audiometry was first performed when the affected individuals V:1 and V:3 were 12 and 9 years old, respectively, and 2 years later. The affected child V:5 was 8 years old when the family was reexamined, and his audiometry was also performed at that

time. All three affected individuals segregate a bilateral, symmetric, moderate-to-severe sensorineural hearing loss (Fig. 1B).

Reports by the parents suggested that the affected individuals had normal hearing until approximately 2 years of age and responded to commands comparable to their unaffected children at the same age. Subsequently, three children were affected by mild hearing loss that rapidly worsened by the time they were 4 years old. A recent study has demonstrated that parental concerns are reliable and one of the major factors in diagnosing hearing defects after children pass newborn hearing screens [Dedhia et al., 2013]. A comparison of the audiometric profile of the three affected individuals (Fig. 1B) also confirms the parents' observation. The youngest individual had better hearing and oral speech as compared with the two older individuals and the oldest affected individual had the highest hearing thresholds. No significant progression of hearing loss for the oldest affected individuals was recorded when audiometry was repeated after 2 years. The three affected individuals in family HLAI-05 do not use hearing aids but still have limited oral speech. The thresholds of hearing of the unaffected individuals varied between 20 and 40 dB



(Fig. 1B). These levels are comparable to thresholds recorded in the normal population in Pakistan when audiometry is conducted in the field [Riazuddin et al., 2000] (Naz S, unpublished data).

The three affected individuals had normal balance as assessed by history and vestibular testing. Independent ambulation was not delayed and was comparable to that of the unaffected siblings. Ophthalmological examinations demonstrated normal, peripheral, and central visual acuity in both daylight and in reduced light. Funduscopy did not detect the presence of retinal abnormalities and electroretinographs were also normal, which ruled out the onset of retinitis pigmentosa at the time of examination. Since detailed medical examination showed the absence of visual and obvious manifestations of any other disorder, we concluded that affected individuals in family HLAI-05 most likely have nonsyndromic hearing loss.

The hearing loss in HLAI-05 did not segregate with any of the reported recessively inherited deafness causing genes. Analyses of genome-wide SNP data identified eight regions in the genome at which marker alleles were homozygous in the two affected individuals and heterozygous in the unaffected mother (Supp. Tables S3 and S4). Genotyping was performed on samples from the whole family with microsatellite markers that spanned these intervals and only linkage to a 30-cM region on chromosome 5q was supported with a LOD score of 2.7 (Fig. 1A). This locus has now been designated as *DFNB101* by HUGO gene nomenclature committee. The mapped interval includes approximately 350 genes, many of which have been reported to exhibit high expression in the inner ear (Shared Harvard Inner Ear Laboratory Database, SHIELD <https://shield.hms.harvard.edu/>). The *DFNB101* candidate region also includes two previously identified genes associated with nonsyndromic hearing loss, *DIAPH1* and *POU4F3*, and two currently unknown dominant deafness gene loci (*DFNA42* and *DFNA54*).

To identify *DFNB101* gene, we analyzed the data after exome sequencing. No mutations were identified in any of the known deafness causing genes. About 97% of the coding exons (including exon-intron boundaries) within the *DFNB101* region were sequenced at coverage greater than 10 $\times$ . We identified three novel variants located in the interval that were absent from dbSNP, exome variant server (<http://evs.gs.washington.edu/EVS/>), and 1000 genome project (<http://www.1000genomes.org/>) datasets: a frameshift variant in *GRXCR2* (p.G239WfsX74) and nonsynonymous variants in *SPOCK1* (p.R110S) and in *PCDHGA12* (p.P220R) (Supp. Table S5). All three variants were confirmed by Sanger sequencing of respective PCR products (Supp. Table S1) and were heterozygous in obligate carriers and homozygous in the affected individuals. The frequency of the three variants was evaluated using DNA samples from ethnically matched controls. The two missense variants were found at frequencies  $\geq 0.05$  and are therefore likely neutral polymorphisms. The third variant, c.714dupT (Chr5:145239330) (Fig. 1C) in *GRXCR2* (Glutaredoxin-like cysteine-rich 2), was absent from 150 normal controls (300 chromosomes). This variant was considered a likely pathogenic mutation primarily due to its severity. Exome variant server does list one among 6,259 individuals who is a carrier for a frameshift mutation in *GRXCR2* (c.252delA, p.I85SfsX33). However, we still considered c.714dupT mutation to be the variant responsible for the phenotype in affected individuals in family HLAI-05 since we expected homozygous mutations to cause hearing loss. Additionally, targeted deletion of the murine ortholog *Grxcr2* causes severe hearing loss in mice [Avenarius, 2012], which supports the role of its ortholog *GRXCR2* in human hearing.

*GRXCR2* comprises three exons (Fig. 2A). The human mRNA and EST sequences of the gene available in the public databases are derived from a source of many pooled tissues. RNAseq data (Illu-

minaBodyMap) indicate that *GRXCR2* has very low expression in the heart, testis, and adrenal gland. Protein expression data (Model Organism Protein Expression Database, [moped.proteinspire.org/](http://moped.proteinspire.org/)) indicates a low titer of *GRXCR2* in blood plasma. This suggests that *GRXCR2* expression is fairly limited in humans, comparable to mice in which all publicly available EST and MPSS signatures are derived from inner ear cDNA libraries.


*GRXCR2* is predicted to encode a protein of 248 amino acids in humans (Fig. 2B). The orthologous proteins exhibit high similarity at the N- and C-termini and are present only in vertebrate genomes (Fig. 2C). Overall, *GRXCR2* is 38% identical and 47% similar to its paralog, *GRXCR1*. Two groups of four cysteines at the C-terminus of *GRXCR2* are predicted to fold into a zinc finger configuration and their arrangement (CX<sub>2</sub>CX<sub>7</sub>CX<sub>2</sub>CX<sub>20</sub>CX<sub>2</sub>CX<sub>7</sub>CX<sub>2</sub>C) is highly conserved in all orthologs (Fig. 2C) and between *GRXCR2* and *GRXCR1*. The mutation c.714dupT is predicted to remove conserved residues, including the last two cysteines from the zinc finger motif, and to generate a protein with an abnormal C-terminal extension (Fig. 2D).

Sanger sequencing of *GRXCR2* did not identify any variants that segregate with hearing loss in the *DFNA42*- (Xua K, personal communication) or *DFNA54*- (Gürtler N, personal communication) linked families. The phenotype in these two families could be due to mutations elsewhere in *GRXCR2* or in different genes. *GRXCR2* mutations were not identified in the remainder of our cohort of moderate-to-severe recessive hearing loss (mostly congenital) or in another collaborative screen of over 600 congenital profound deafness cases (Avenarius et al., submitted), suggesting that *GRXCR2* may not be a frequent cause of this type of genetic deafness.


To evaluate potential effects of the c.714dupT variant, we prepared *GRXCR2* expression constructs that encoded myc-tagged, wild-type *GRXCR2* (myc-*GRXCR2*<sup>wt</sup>) or the C-terminal truncation/extension protein predicted from the c.714dupT variant, also tagged with a myc epitope (myc-*GRXCR2*<sup>var</sup>). We transfected the wild type and c.714dupT variant constructs into an epithelial cell line, LLC-PK1-CL4 (CL4) using previously described methods [Loomis et al., 2003]. CL4 cells are derived from porcine kidney and have been used as models of epithelial cells [Loomis et al., 2003]. In addition, CL4 microvilli have similarity to hair cell stereocilia and undergo dimensional changes upon expression of proteins such as the actin bundling protein espin, consistent with espin's role in stereocilia morphogenesis in vivo [Loomis et al., 2003]. Following transfection of an expression construct encoding wild-type, myc-tagged *GRXCR2* (myc-*GRXCR2*<sup>wt</sup>), high levels of anti-myc immunoreactivity were observed near the apical surface of CL4 cells (Fig. 3A-C, A'-C'). This signal was closely associated with actin filaments on the apical surface of the cells, consistent with selective localization of *GRXCR2*<sup>wt</sup> to microvilli (Supp. Fig. S1). Similar localization has been demonstrated in CL4 cells transfected with mouse *Grxcr1* [Odeh et al., 2010] and *Grxcr2* (Kohrman DC, unpublished data) and suggests that human *GRXCR2*, like these related proteins, also resides in the stereocilia of sensory hair cells in the inner ear in vivo. In contrast, only a small fraction (less than 5%) of CL4 cells transfected with the myc-*GRXCR2*<sup>var</sup> construct exhibited myc-immunoreactivity (Fig. 3D-F, D'-F'), which was present at lower levels in the cytoplasm rather than in microvilli. The majority of *GRXCR2*<sup>var</sup>-transfected cells (greater than 95% of GFP-positive cells) exhibited little or no specific immunoreactivity (Supp. Fig. S2).

Western analysis of whole-cell protein lysates prepared from transfected human embryonic kidney 293T cells indicated much reduced steady-state levels of *GRXCR2*<sup>var</sup> relative to *GRXCR2*<sup>wt</sup>





**Figure 3.** Expression of wild-type and mutant GRXCR2 in epithelial cells. **A–C:** Myc-tagged GRXCR2<sup>wt</sup> localized to the apical region of transfected CL4 epithelial cells. Myc-GRXCR2<sup>wt</sup> immunoreactivity (**A**) and coexpressed GFP (**B**) are indicated in gray scale, maximum projection images of two representative cells. (**C**) is a merged color image of myc-GRXCR2<sup>wt</sup> (red) and GFP (green) in addition to nuclear staining (blue; Hoechst reagent). Scale bars represent 10  $\mu$ m. **A'–C':** Corresponding orthogonal x, z sections demonstrate the apical localization of myc-GRXCR2<sup>wt</sup> (**A', C'**) relative to the broad cytoplasmic localization of GFP (**B', C'**). **D–F:** Lower levels of myc-tagged GRXCR2<sup>var</sup> localized to the cytoplasm of transfected CL4 epithelial cells. Myc-GRXCR2<sup>var</sup> immunoreactivity (**D**) and coexpressed GFP (**E**) are indicated in a gray scale, maximum projection image of a representative cell. (**F**) is a merged color image of myc-GRXCR2<sup>var</sup> (red) and GFP (green) in addition to nuclear staining (blue). Scale bars represent 10  $\mu$ m. **D'–F':** Corresponding orthogonal x, z sections demonstrate the cytoplasmic colocalization of myc-GRXCR2<sup>var</sup> (**D', F'**) and GFP (**E', F'**).



**Figure 4.** The GRXCR2 c.714dupT variant produces an unstable protein. Human 293T cells were transfected with the myc-tagged GRXCR2<sup>wt</sup> or GRXCR2<sup>var</sup> expression constructs, the vector control plasmid, or were mock transfected. Duplicate transfections were treated with 20  $\mu$ M proteasome inhibitor MG132 (+) or with ethanol vehicle (-). Western analysis of whole-cell protein lysates from the transfected cells indicated GRXCR2<sup>wt</sup> steady-state levels were significantly higher than GRXCR2<sup>var</sup> levels, which were increased following proteasome inhibition. The positions of myc-GRXCR2<sup>wt</sup> (expected molecular weight: 29.5 kDa) and myc-GRXCR2<sup>var</sup> (expected molecular weight: 36.7 kDa) are indicated (top panel). The anti-myc antibody also recognizes the cellular c-myc protein, levels of which are stabilized by proteasome inhibitors. The levels of GFP indicate comparable transfection efficiencies of each construct (bottom panel).

extension of the protein. This 63 amino acid C-terminal extension does not contain sequence homology or domains similar to known proteins. However, the extension introduces an N-glycosylation motif (NISL) that can facilitate the degradation of proteins that fail to achieve their native conformation [Vembar and Brodsky, 2008]. Consistent with this notion, our cell transfection assays with variant GRXCR2 suggested that the mutant protein is unstable.

GRXCR2 is a paralog of GRXCR1. Mutations of GRXCR1 cause moderate-to-profound hearing loss in humans [Odeh et al., 2010; Schraders et al., 2010]. In addition, several independent, loss-of-function alleles of *Grxcr1* result in deafness in *pirouette* mice [Odeh et al., 2010]. GRXCR1 orthologs are present in diverse metazoan species in contrast to GRXCR2 orthologs, which are limited to the vertebrate genomes. GRXCR2 orthologs have conserved N- and C-termini, whereas the central portion is the most diverse and has similarity to glutaredoxins. Glutaredoxins are enzymes that reduce oxidized cysteines of proteins, using glutathione as an electron donor [Holmgren, 2000]. However, the paired catalytic cysteine residues present in active glutaredoxins and the three amino acids that are predicted to be required for contact with glutathione [Holmgren, 1989] are absent from GRXCR2. This suggests that the central domain of GRXCR2 does not possess glutaredoxin activity.

The GRXCR1 and GRXCR2 homolog *thrumin1* (*A. thaliana*) encodes a protein that also lacks the sites important for enzymatic activity and does not have a demonstrated catalytic function.



THRUMIN1 is required for light-induced chloroplast movement, during which its actin bundling activity appears to facilitate linkage between the plasma membrane of the chloroplast and the underlying actin cytoskeleton [Whippo et al., 2011]. PLP2, another oxidoreductase superfamily member, also lacks catalytic cysteine residues and, through interactions with chaperone TCP-1, facilitates the folding of cytosolic actins in yeast [McCormack et al., 2009]. Stereocilia of the mammalian inner ear also contain cytoplasmic  $\beta$ - and  $\gamma$ -actin. GRXCR2 is localized to the stereocilia in the mouse inner ear [Avenarius, 2012]. The actin bundling and folding functions of these homologs suggest a similar role of GRXCR2 in the development of stereocilia bundles in the mammalian inner ear.

The targeted *Grxcr2* mouse mutant exhibits hearing loss that is early onset and progressive in nature [Avenarius, 2012] comparable to the loss that we have demonstrated in individuals with mutation in *GRXCR2*. Hearing loss in the mouse *Grxcr2* mutant is associated with defects in the early development and later maintenance of stereocilia bundle organization. The similarity in the human phenotype with targeted mice mutant suggests a comparable requirement of the protein for the maintenance of cochlear function in both species.

## Acknowledgments

We express our gratitude to family HLAI-05 and other participants for their cooperation. We are grateful to Mr. Muhammad Usman for referring the family for our research, Dr. Ijaz Javed and Dr. Aslam Awanat Allied Hospital Faisalabad for conducting ERG, and ENT examination and Dr. Zeeshan Ahmad at Layton Rehmatullah Benevolent Trust (LRBT), Lahore for funduscopy. We gratefully acknowledge Jessica Winkels and Andrew Riedy for excellent technical assistance in the transfection experiments and Tom Carey and Thankam Nair for providing human inner ear RNA samples. We are grateful to Ms. Iram Aziz for her help. We thank Dr. Thomas Friedman, Dr. Robert Morell, and Dr. Inna Belyantseva for reviewing the manuscript and helpful suggestions.

*Disclosure statement:* The authors declare no conflict of interest.

## References

- Amir el AD, Bartal O, Morad E, Nagar T, Sheynin J, Parvari R, Chalifa-Caspi V. 2010. KinSNP software for homozygosity mapping of disease genes using SNP microarrays. *Hum Genom* 4:394–401.
- Avenarius MR. 2012. *The Glutaredoxin-like cysteine-rich family of genes, Grxcr1 and Grxcr2, in stereocilia development and function*. PhD Thesis, Ann Arbor, MI: The University of Michigan. p 173.
- Choi BY, Kim DH, Chung T, Chang M, Kim EH, Kim AR, Seok J, Chang SO, Bok J, Kim D, Oh SH, Park WY. 2013. Destabilization and mislocalization of POU3F4 by C-terminal frameshift truncation and extension mutation. *Hum Mutat* 34:309–316.
- Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. 2004. Automatic and quantitative measurement of protein–protein colocalization in live cells. *Biophys J* 86:3993–4003.
- Dedhia K, Kitsko D, Sabo D, Chi DH. 2013. Children with sensorineural hearing loss after passing the newborn hearing screen. *JAMA Otolaryngol Head Neck Surg* 139:1–5.
- Gamsjaeger R, Liew CK, Loughlin FE, Crossley M, Mackay JP. 2007. Sticky fingers: zinc-fingers as protein-recognition motifs. *Trends Biochem Sci* 32:63–70.
- Giroto G, Abdulhadi K, Buniello A, Vozzi D, Licastro D, d'Eustacchio A, Vuckovic D, Alkowari MK, Steel KP, Badii R, Gasparini P. 2013. Linkage study and exome sequencing identify a BDP1 mutation associated with hereditary hearing loss. *PLoS One* 8:e80323.
- Holmgren A. 1989. Thioredoxin and glutaredoxin systems. *J Biol Chem* 264:13963–13966.
- Holmgren A. 2000. Antioxidant function of thioredoxin and glutaredoxin systems. *Antioxid Redox Signal* 2:811–820.
- Horn HF, Brownstein Z, Lenz DR, Shivatzki S, Dror AA, Dagan-Rosenfeld O, Friedman LM, Roux KJ, Kozlov S, Jeang KT, Frydman M, Burke B, et al. 2013. The LINC complex is essential for hearing. *J Clin Invest* 123:740–750.
- Imtiaz A, Naz S. 2012. A rapid and cost-effective protocol for screening known genes for autosomal recessive deafness. *Pak J Zool* 44:641–647.
- Loomis PA, Zheng L, Sekerkova G, Changyaleket B, Mugnaini E, Bartles JR. 2003. Espin cross-links cause the elongation of microvillus-type parallel actin bundles in vivo. *J Cell Biol* 163:1045–1055.
- McCormack EA, Altschuler GM, Dekker C, Filmore H, Willison KR. 2009. Yeast phosphatidylethanolamine transfer protein 2 acts as a stimulatory co-factor for the folding of actin by the chaperonin CCT via a ternary complex. *J Mol Biol* 391:192–206.
- Naz S. 2012. Genetics of nonsyndromic recessively inherited moderate to severe and progressive deafness in humans. In: Naz S, editor. *Hearing loss*. Croatia: Intech. p 247–274.
- Odeh H, Hunker KL, Belyantseva IA, Azaiez H, Avenarius MR, Zheng L, Peters LM, Gagnon LH, Hagiwara N, Skynner MJ, Brilliant MH, Allen ND, et al. 2010. Mutations in *Grxcr1* are the basis for inner ear dysfunction in the pirouette mouse. *Am J Hum Genet* 86:148–160.
- Riazaudin S, Castelein CM, Ahmed ZM, Lalwani AK, Mastroianni MA, Naz S, Smith TN, Liburd NA, Friedman TB, Griffith AJ, Riazaudin S, Wilcox ER. 2000. Dominant modifier *DFNM1* suppresses recessive deafness *DFNB26*. *Nat Genet* 26:431–434.
- Schraders M, Lee K, Oostrik J, Huygen PL, Ali G, Hoefsloot LH, Veltman JA, Cremers FP, Basit S, Ansar M, Cremers CW, Kunst HP, et al. 2010. Homozygosity mapping reveals mutations of *GRXCR1* as a cause of autosomal-recessive nonsyndromic hearing impairment. *Am J Hum Genet* 86:138–147.
- Schraders M, Ruiz-Palmero L, Kalay E, Oostrik J, del Castillo FJ, Sezgin O, Beynon AJ, Strom TM, Pennings RJ, Seco CZ, Oonk AM, Kunst HP, et al. 2012. Mutations of the gene encoding otogelin are a cause of autosomal-recessive nonsyndromic moderate hearing impairment. *Am J Hum Genet* 91:883–889.
- Schrauwen I, Helfmann S, Inagaki A, Predoehl F, Tabatabaiefar MA, Picher MM, Sommen M, Seco CZ, Oostrik J, Kremer H, Dheedene A, Claes C, et al. 2012. A mutation in *CABP2*, expressed in cochlear hair cells, causes autosomal-recessive hearing impairment. *Am J Hum Genet* 91:636–645.
- Vembar SS, Brodsky JL. 2008. One step at a time: endoplasmic reticulum-associated degradation. *Nat Rev Mol Cell Biol* 9:944–957.
- Whippo CW, Khurana P, Davis PA, DeBlasio SL, DeSloover D, Staiger CJ, Hangarter RP. 2011. THRUMIN1 is a light-regulated actin-bundling protein involved in chloroplast motility. *Curr Biol* 21:59–64.
- Yariz KO, Duman D, Seco CZ, Dallman J, Huang M, Peters TA, Sirmaci A, Lu N, Schraders M, Skromne I, Oostrik J, Diaz-Horta O, et al. 2012. Mutations in *OTOGL*, encoding the inner ear protein otogelin-like, cause moderate sensorineural hearing loss. *Am J Hum Genet* 91:872–882.